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The second issue of volume two of Therapeutics and Clinical Risk Management
contains a diverse selection of comprehensive review articles and original research
papers from leading authors around the world.
Disseminated fungal infection rates are rising as a consequence of the increased
potency and use of immunosuppressant agents as therapy in cancer and
transplantation; increased numbers of AIDS patients; and growing numbers of patients
with additional risk factors for this type of infection. Although newer antifungals
such as fluconazole show less toxicity and a greater activity spectrum than do older
drugs, several of the preparations in this class demonstrate limited effectiveness,
resistance, or erratic oral bioavailability; in addition, mortality from disseminated
fungal infection remains at an unacceptable level. Voriconazole, a synthetic derivative
of fluconazole, is a member of the second generation of triazoles and our first review,
from Pemán and colleagues, considers the efficacy and pharmacokinetics of this
broad-spectrum antifungal agent.
It is only relatively recently that the importance of oral mucositis as a side-effect
of antitumour therapy has been recognized. This distressing condition not only impacts
profoundly on the patient’s quality of life but also increases the potential for life-
threatening infections and frequently adversely affects the administration of optimal
therapeutic regimens through delayed, decreased or discontinued dosing. Following
the publication of internationally recognized guidelines for the management of oral
mucositis, D’Hondt and colleagues’ timely review summarizes its epidemiology,
pathophysiology, and the patient- and therapy-associated risk factors associated with
its development. The authors also review recent advances in drug therapy for the
prevention and treatment of this potentially devastating condition. The recombinant
human keratinocyte growth factor, Palifermin, has proved highly effective in the
management of cancer treatment-induced toxicity and the authors provide a thorough
overview whilst also emphasizing the importance of non-drug elements of prevention,
including systematic oral care and good patient information.
The increase in antibiotic resistant strains of microorganisms is of major concern
to healthcare and public health professionals and emphasizes the necessity for the
development of new and more effective treatments. Daptomycin, a cyclic lipopeptide
antibiotic, has a broad spectrum of activity against both aerobic and anaerobic gram-
positive organisms and is currently approved for use in skin and soft-tissue infections.
Shoemaker and colleagues review its effectiveness in these conditions and consider
potential adverse effects and the likelihood of the development of resistance by the
target organisms. It appears that daptomycin’s unique mechanism of action may allow
its use to be extended to the treatment of endocarditis, meningitis, ventriculitis, and
peritonitis. The authors provide a useful review of its role in these conditions.
Anemia is a frequent problem during cancer therapy and may be in part a result
of tumour-related comorbidities or a side effect of chemo- or radiotherapy. Treatment
is reliant either on transfusion or administration of recombinant human erythropoietin.
Human erythropoietin therapy has well documented clinical benefits, but frequent
dosing is required and response rates can vary between individuals. Wauters and co-
authors present a comprehensive review of Darbepoetin alfa, a novel erythropoietic
protein with a unique molecular structure, in terms of its clinical development and
efficacy. The emphasis on recently published findings including two large, phase III,Therapeutics and Clinical Risk Management 2006:2(2) 128
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placebo-controlled trials in patients with solid tumors and
hematological malignancies; data from these trials
demonstrated that Darbepoetin alfa treatment was effective,
safe and well-tolerated. The authors also discuss the future
potential of optimal iron supplementation strategy and the
effect of Darbepoetin alfa therapy on patient survival.
Our next review by Richard Shelton is of great interest
as it summarizes the data supporting the introduction in the
US of a fixed combination of the atypical antipsychotic
olanzapine and the serotonin selective reuptake inhibitor
antidepressant fluoxetine (Symbiax
TM) for the treatment of
bipolar depression. This is a controversial area as although
fixed combinations of drugs of these classes were once
common in neuropsychiatry, their use was discontinued as
a majority of patients receiving such a regimen were under-
dosed for depression against a backdrop of high rates of
overdose and suicide. The author concludes that although
Symbiax is an important alternative for bipolar depression,
uptake by practitioners has been limited due to a number of
concerns regarding olanzapine use including weight gain,
elevated lipid levels, and increased risk of Type II diabetes.
Higher intraocular pressure (IOP) is considered to be a
major risk factor for glaucoma, the second leading cause of
blindness world-wide. Robert Noecker has provided a
comprehensive review of recent advances in and current
approaches to the management of glaucoma and intraocular
hypertension. Although glaucoma causes significant
morbidity it can be effectively prevented and/or treated in
many patients. Recent availability of more powerful ocular
hypotensives and an enhanced awareness of the benefits of
achieving the lowest IOP possible for each patient have
resulted in a significantly more aggressive treatment
paradigm. Selection of an ocular hypotensive agent should
be based on the primary therapeutic objective of early and
aggressive intervention in order to preserve the visual field.
The author reviews the clinical efficacy, mechanism of
action, safety and tolerability profiles, convenience and
compliance of frequently used glaucoma medications.
Rheumatoid arthritis (RA) is a chronic systemic
inflammatory disorder. However, while poor disease control
leads to joint pain and deformity with consequent
functional impairment and loss of independence, patients
may also experience significant systemic illness including
nodules, vasculitis, pulmonary fibrosis and nerve
entrapment. Both RA and extra-articular disease are
associated with B cell production of the autoantibody
termed rheumatoid factor. Thus there has been much
interest in strategies to deplete B cells including the use
of the anti-CD20 antibody, rituximab. Our last review
by Bryant and Moore provides an overview of the
rationale for and experience with rituximab in RA.
Several recent studies using rituximab have demonstrated
significant declines in RA activity thereby providing
evidence for the role of B cells in RA. The authors
conclude that rituximab is a major addition to the
increasing therapeutic options for the treatment of
patients with RA.
The first original research paper in this issue is from
Ständer and colleagues who report interesting findings on
the efficacy of the topical calcineurin inhibitors tacrolimus
and pimecrolimus in diseases such as prurigo nodularis,
generalized and localized pruritus including genitoanal
pruritus. Topical calcineurin inhibitors have been shown to
rapidly reduce eczematous lesions and give rapid relief of
pruritus in atopic dermatitis patients. The results presented
in this study suggest that calcineurin inhibitors may be
helpful in a subgroup of patients with prurigo nodularis.
However, additional larger-scale studies will be required to
further evaluate the efficacy of tacrolimus and pimecrolimus
in prurigo nodularis.
Our final original research paper has looked at the costs
and benefits of influenza vaccination in a group of
employees of an Italian District Health Authority. This is
an interesting area of research since influenza is the third
infectious cause of death in first world countries with
significant attendant morbidity. The results presented here
suggest that the influenza vaccination strategy was cost-
saving and that the economic evaluation used in this study
might be applicable to other vaccination strategies in other
settings.